13.45
1.22 (9.98%)
| Penutupan Terdahulu | 12.23 |
| Buka | 12.23 |
| Jumlah Dagangan | 966,833 |
| Purata Dagangan (3B) | 553,379 |
| Modal Pasaran | 680,880,512 |
| Harga / Jualan (P/S) | 3.89 |
| Harga / Buku (P/B) | 3.83 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -100.62% |
| Margin Operasi (TTM) | 13.62% |
| EPS Cair (TTM) | -3.09 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 469.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 48.70% |
| Nisbah Semasa (MRQ) | 2.93 |
| Aliran Tunai Operasi (OCF TTM) | -84.04 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -56.82 M |
| Pulangan Atas Aset (ROA TTM) | -17.56% |
| Pulangan Atas Ekuiti (ROE TTM) | -47.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | REGENXBIO Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.50 |
|
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.70% |
| % Dimiliki oleh Institusi | 87.65% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 52.00 (Chardan Capital, 286.62%) | Beli |
| Median | 34.00 (152.79%) | |
| Rendah | 19.00 (RBC Capital, 41.26%) | Beli |
| Purata | 35.00 (160.22%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 10.86 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 20 Nov 2025 | 52.00 (286.62%) | Beli | 10.87 |
| 08 Sep 2025 | 52.00 (286.62%) | Beli | 9.48 | |
| RBC Capital | 07 Nov 2025 | 19.00 (41.26%) | Beli | 11.21 |
| HC Wainwright & Co. | 07 Oct 2025 | 34.00 (152.79%) | Beli | 10.51 |
| 08 Sep 2025 | 34.00 (152.79%) | Beli | 9.48 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Nov 2025 | Pengumuman | REGENXBIO to Participate in Upcoming Investor Conference |
| 06 Nov 2025 | Pengumuman | REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights |
| 30 Oct 2025 | Pengumuman | REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program |
| 29 Oct 2025 | Pengumuman | REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights |
| 15 Oct 2025 | Pengumuman | REGENXBIO to Participate in Upcoming Investor Conferences |
| 09 Oct 2025 | Pengumuman | REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting |
| 06 Oct 2025 | Pengumuman | REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD |
| 29 Sep 2025 | Pengumuman | REGENXBIO Announces Presentation at the World Muscle Society |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |